Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Rises By 217.0%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 398,714 shares, a growth of 217.0% from the August 15th total of 125,762 shares. Based on an average daily volume of 3,391,068 shares, the days-to-cover ratio is currently 0.1 days. Approximately 2.9% of the company’s shares are short sold.

Catheter Precision Trading Up 6.1%

Shares of NYSEAMERICAN VTAK traded up $0.01 during mid-day trading on Friday, reaching $0.17. 712,209 shares of the company’s stock were exchanged, compared to its average volume of 2,238,078. The company’s 50-day moving average is $0.36 and its 200-day moving average is $0.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.18 and a current ratio of 0.19. The firm has a market capitalization of $2.52 million, a price-to-earnings ratio of -0.03 and a beta of -1.03. Catheter Precision has a 52-week low of $0.16 and a 52-week high of $3.20.

Catheter Precision (NYSEAMERICAN:VTAK) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($19.00) by $18.08. The firm had revenue of $1.02 million for the quarter, compared to analyst estimates of $2.00 million. Catheter Precision had a negative net margin of 656.03% and a negative return on equity of 37.53%.

Hedge Funds Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC acquired a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent filing with the SEC. Institutional investors and hedge funds own 20.34% of the company’s stock.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.